Accessibility Menu
Athersys logo

Athersys(OTC) ATHX

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2007)-100%
5 Year-100%
1 Year+0%
1 Month+0%
N/A
Athersys last closing stock price
MetricPriceDate
Last closeUSD 0.002026-08-31
Athersys stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-08-24
1 month+0%USD 0.002026-07-30
3 month+0%USD 0.002026-06-02
Year to date+0%USD 0.002025-12-31
1 year+0%USD 0.002025-08-29
3 year-100%USD 0.472023-09-01
5 year-100%USD 41.752021-09-01
Since inception-100%USD 131.252007-06-12

Athersys Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$80.00K

Net Income (TTM)

-$37.51M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Nov 14, 2024

ATHX News

Japanese scientists in a lab

Why Athersys Stock Jumped Today

Keith SpeightsMar 31, 2021
Scientist looking through microscope

Why Athersys Stock Jumped Today

Keith SpeightsDec 21, 2020
paper airplanes rising

Here's Why Athersys Stock Is Soaring Today

Maxx ChatskoJun 25, 2020
blocks arrows rising

Here's Why Athersys Rose 26.5% in May

Maxx ChatskoJun 9, 2020
multiple lines down

Here's Why Athersys Tumbled 23.3% in April

Maxx ChatskoMay 4, 2020
557 doctor visit

Are Stem Cells the COVID-19 Treatment We've All Been Waiting For?

Maxx ChatskoApr 28, 2020
076 arrow dude getty

Here's Why Athersys Rose as Much as 15.2% Today

Maxx ChatskoMay 14, 2019
dude tossing stacks

Here's Why Athersys Is Soaring Today

Maxx ChatskoApr 23, 2019
Page 1

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Athersys

Athersys, Inc. is a biotechnology company focused on regenerative medicine, developing innovative therapies for various health conditions. The company's flagship product, MultiStem, is an allogeneic stem cell treatment currently undergoing Phase III clinical trials for multiple applications.

Products and Services
  • MultiStem: A stem cell therapy for neurological damage and other conditions
  • Veterinary applications of MultiStem for tissue regeneration in animals
  • Collaborative research initiatives with Healios K.K. and the University of Minnesota
Growth Outlook
  • MultiStem is in Phase III trials, indicating significant progress towards commercialization
  • Partnerships with Healios K.K. enhance market reach and development capabilities
  • Focus on addressing unmet medical needs in both human and veterinary medicine
Financial Highlights
  • Q3 2023 net income of -$3.77 million, showing ongoing investment in R&D
  • Cash and cash equivalents of $1.02 million as of September 30, 2023
  • Trailing twelve months (TTM) revenue of $49,000, reflecting early-stage commercialization efforts
Athersys, Inc. operates in a dynamic sector with a focus on innovative therapies that address critical health challenges. The company's commitment to research and development is evident in its substantial investments, particularly in the MultiStem platform. Despite recent financial losses, the ongoing clinical trials and strategic partnerships position Athersys for potential growth in the regenerative medicine market. The company's focus on both human and veterinary applications of its therapies further diversifies its market opportunities. Investors may find Athersys an intriguing option as it navigates the complexities of biotechnology development and seeks to bring its innovative solutions to market.
AI Generated • Aug 23, 2026

Industry

Biotechnology

Sector

Health Care

Employees

24

CEO

Daniel A. Camardo, MBA

Website

www.athersys.com

Headquarters

Cleveland, OH 44115-2634, US

ATHX Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

-1446.18%

Net Income Margin

-1278.14%

Return on Equity

1819.33%

Return on Capital

N/A

Return on Assets

-245.43%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$81.00K

Operating Income

-$41.76M

EBITDA

-$40.75M

Operating Cash Flow

-$26.36M

Capital Expenditure

$1.65M

Free Cash Flow

-$24.71M

Cash & ST Invst.

$1.02M

Total Debt

$18.58M

Athersys Performance Analysis

Athersys annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 5,514,000N/A
20222022-12-31USD 5,325,000-3.4%
Athersys sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42022-12-31-52.3%
Q12023-03-31-100.0%
Q22023-06-30N/A
Q32023-09-30-100.0%
Athersys annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -9.69N/A
20222022-12-31USD -6.07-37.4%
Athersys sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42022-12-317.8%
Q12023-03-3145.8%
Q22023-06-30-37.8%
Q32023-09-3075.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2023YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

$0.00

-100.0%

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

24

N/A

Net Income

-$3.77M

+72.4%

EBITDA

-$6.80M

+57.7%

Quarterly Fundamentals

Name
Q3 2023YOY CHG

Total Cash

$1.02M

-92.6%

Total Debt

$18.58M

+107.5%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$18.58M

+2098.5%

Return on Assets

-2.45%

N/A

Return on Invested Capital

5.26%

N/A

Free Cash Flow

-$3.85M

+63.7%

Operating Cash Flow

-$3.85M

+63.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
INFIQInfinity Pharmaceuticals, Inc.
$0.00+0.00%
NEPTFNeptune Wellness Solutions Inc.
$0.00+0.00%
WENAAnew Medical, Inc.
$0.73-3.84%
NMTRQ9 Meters Biopharma, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.29-0.07%
NVDANvidia
$217.44-0.02%
INTCIntel
$88.48-0.01%
NUNu Holdings
$14.48-0.01%

Questions About ATHX

What is the current price of Athersys?

Athersys is trading at N/A per share.

What is the 52-week range for Athersys?

Over the past 52 weeks, Athersys has traded between N/A and N/A.

How much debt does Athersys have?

As of the most recent reporting period, Athersys reported total debt of $8.69M.

How much cash does Athersys have on hand?

Athersys reported $9.04M in cash and cash equivalents in its most recent financial results.

What is Athersys’s dividend yield?

Athersys does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services